TY - JOUR
T1 - Review of Bleeding and Thrombotic Risks Associated With Antithrombotic Therapy After Transcatheter Structural Heart Interventions
AU - Kawashima, Hideyuki
AU - Numasawa, Yohei
AU - Hayakawa, Naoki
AU - Asano, Taku
AU - Tanaka, Shigemitsu
AU - Torii, Sho
AU - Ueshima, Daisuke
AU - Hishikari, Keiichi
AU - Hioki, Hirofumi
AU - Watanabe, Yusuke
AU - Mizutani, Kazuki
AU - Matsuo, Yae
AU - Hayashida, Kentaro
AU - SUNRISE Lab Investigators
AU - Jujo, Kentaro
AU - Nakazawa, Gaku
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024/1
Y1 - 2024/1
N2 - Transcatheter structural heart interventions have drastically evolved over the past 2 decades. However, most catheterization procedures require the deployment of devices in the body; therefore, the adhesion of thrombi to those devices is a major problem, resulting in the requirement of a period of postprocedural antithrombotic regimen. However, in recent years, bleeding associated with these antithrombotic therapies has also become a major concern, attracting the attention of investigators. This is complicated by the fact that patients at high thrombotic risk are also at high bleeding risk, making the issue of administrating antithrombotic therapy challenging. The objective of this review was to identify the important issues and summarize the current status of postoperative antithrombotic therapy and assessment of the bleeding risk following transcatheter structural heart interventions such as transcatheter aortic valve replacement, transcatheter edge-to-edge repair, and transcatheter left atrial appendage occlusion.
AB - Transcatheter structural heart interventions have drastically evolved over the past 2 decades. However, most catheterization procedures require the deployment of devices in the body; therefore, the adhesion of thrombi to those devices is a major problem, resulting in the requirement of a period of postprocedural antithrombotic regimen. However, in recent years, bleeding associated with these antithrombotic therapies has also become a major concern, attracting the attention of investigators. This is complicated by the fact that patients at high thrombotic risk are also at high bleeding risk, making the issue of administrating antithrombotic therapy challenging. The objective of this review was to identify the important issues and summarize the current status of postoperative antithrombotic therapy and assessment of the bleeding risk following transcatheter structural heart interventions such as transcatheter aortic valve replacement, transcatheter edge-to-edge repair, and transcatheter left atrial appendage occlusion.
KW - antithrombotic therapy
KW - bleeding risk
KW - transcatheter aortic valve replacement
KW - transcatheter edge-to-edge repair
KW - transcatheter structural heart interventions
UR - http://www.scopus.com/inward/record.url?scp=85176578635&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jacasi.2023.08.004
DO - https://doi.org/10.1016/j.jacasi.2023.08.004
M3 - Review article
C2 - 38222261
SN - 2772-3747
VL - 4
SP - 1
EP - 9
JO - JACC: Asia
JF - JACC: Asia
IS - 1
ER -